Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 3
1948 2
1950 1
1951 2
1952 3
1953 2
1954 1
1955 2
1956 3
1957 4
1958 7
1959 13
1960 31
1961 62
1962 76
1963 172
1964 293
1965 201
1966 229
1967 316
1968 370
1969 408
1970 482
1971 635
1972 627
1973 753
1974 821
1975 856
1976 833
1977 797
1978 915
1979 904
1980 850
1981 938
1982 1018
1983 1159
1984 1309
1985 1334
1986 1295
1987 1313
1988 1267
1989 1476
1990 1523
1991 1517
1992 1458
1993 1533
1994 1476
1995 1473
1996 1559
1997 1521
1998 1497
1999 1523
2000 1644
2001 1655
2002 1650
2003 1698
2004 1590
2005 1847
2006 1891
2007 1964
2008 1888
2009 1973
2010 2060
2011 2236
2012 2337
2013 2285
2014 2308
2015 2380
2016 2272
2017 2167
2018 2225
2019 2297
2020 2515
2021 2562
2022 2375
2023 2189
2024 1290

Text availability

Article attribute

Article type

Publication date

Search Results

82,478 results

Results by year

Filters applied: . Clear all
Page 1
Cyclophosphamide and cancer: golden anniversary.
Emadi A, Jones RJ, Brodsky RA. Emadi A, et al. Nat Rev Clin Oncol. 2009 Nov;6(11):638-47. doi: 10.1038/nrclinonc.2009.146. Epub 2009 Sep 29. Nat Rev Clin Oncol. 2009. PMID: 19786984 Review.
Cyclophosphamide remains one of the most successful and widely utilized antineoplastic drugs. ...We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases....
Cyclophosphamide remains one of the most successful and widely utilized antineoplastic drugs. ...We also discuss the development of h
Cyclophosphamide in dermatology.
Kim J, Chan JJ. Kim J, et al. Australas J Dermatol. 2017 Feb;58(1):5-17. doi: 10.1111/ajd.12406. Epub 2016 Jan 24. Australas J Dermatol. 2017. PMID: 26806212 Review.
Cyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely used to treat malignancies and severe manifestations of various auto-immune diseases. ...This article reviews the current literature on
Cyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely
Cyclophosphamide cardiotoxicity.
Kumar S, Gupta RK, Samal N. Kumar S, et al. Natl Med J India. 1992 Jan-Feb;5(1):17-9. Natl Med J India. 1992. PMID: 1304238 Free article. Review. No abstract available.
Clinical pharmacokinetics of cyclophosphamide.
Moore MJ. Moore MJ. Clin Pharmacokinet. 1991 Mar;20(3):194-208. doi: 10.2165/00003088-199120030-00002. Clin Pharmacokinet. 1991. PMID: 2025981 Review.
Cyclophosphamide has been in clinical use for the treatment of malignant disease for over 30 years. ...Cyclophosphamide is used in doses that range from 1.5 to 60 mg/kg/day. ...
Cyclophosphamide has been in clinical use for the treatment of malignant disease for over 30 years. ...Cyclophosphamide is use
Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight.
McCurdy SR, Luznik L. McCurdy SR, et al. Blood Rev. 2023 Nov;62:101093. doi: 10.1016/j.blre.2023.101093. Epub 2023 Apr 28. Blood Rev. 2023. PMID: 37198064 Review.
However, benefits in relapse reduction were outweighed by a high risk of graft-versus-host disease (GVHD) when using conventional pharmacological immunosuppression. Post-transplant cyclophosphamide(PTCy)-based platforms abated the risk of GVHD thereby overcoming the negati …
However, benefits in relapse reduction were outweighed by a high risk of graft-versus-host disease (GVHD) when using conventional pharmacolo …
Metabolism of oxazaphosphorines.
Sladek NE. Sladek NE. Pharmacol Ther. 1988;37(3):301-55. doi: 10.1016/0163-7258(88)90004-6. Pharmacol Ther. 1988. PMID: 3290910 Review. No abstract available.
Metabolism and pulmonary toxicity of cyclophosphamide.
Patel JM. Patel JM. Pharmacol Ther. 1990;47(1):137-46. doi: 10.1016/0163-7258(90)90049-8. Pharmacol Ther. 1990. PMID: 2195554 Review.
Pulmonary toxicity caused by an antineoplastic drug, cyclophosphamide is becoming a more frequently recognized entity. Metabolism of cyclophosphamide in lung to alkylating metabolites and acrolein, a reactive aldehyde are in part responsible for pulmonary toxicity. …
Pulmonary toxicity caused by an antineoplastic drug, cyclophosphamide is becoming a more frequently recognized entity. Metabolism of …
Cyclophosphamide cardiotoxicity.
von Bernuth G, Adam D, Hofstetter R, Lang D, Mohr W, Kohne E, Niethammer D. von Bernuth G, et al. Eur J Pediatr. 1980 Jun;134(1):87-90. doi: 10.1007/BF00442410. Eur J Pediatr. 1980. PMID: 6997053
A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide (4 x 50 mg/kg on four consecutive days) given as preparation for bone marrow grafting. ...
A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide
Cyclophosphamide in vitiligo.
Gokhale BB, Parakh AP. Gokhale BB, et al. Indian J Dermatol. 1983 Jan;28(1):7-10. Indian J Dermatol. 1983. PMID: 6852882 No abstract available.
Clinical pharmacokinetics of cyclophosphamide.
Grochow LB, Colvin M. Grochow LB, et al. Clin Pharmacokinet. 1979 Sep-Oct;4(5):380-94. doi: 10.2165/00003088-197904050-00004. Clin Pharmacokinet. 1979. PMID: 389529 Review. No abstract available.
82,478 results
You have reached the last available page of results. Please see the User Guide for more information.